122 related articles for article (PubMed ID: 8033956)
21. Derivation of urinary dopamine from plasma dopa.
Zimlichman R; Levinson PD; Kelly G; Stull R; Keiser HR; Goldstein DS
Clin Sci (Lond); 1988 Nov; 75(5):515-20. PubMed ID: 3151165
[TBL] [Abstract][Full Text] [Related]
22. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Buck K; Ferger B
Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
[TBL] [Abstract][Full Text] [Related]
23. DOPA, dopamine, and DOPAC concentrations in the rat gastrointestinal tract decrease during fasting.
Eldrup E; Richter EA
Am J Physiol Endocrinol Metab; 2000 Oct; 279(4):E815-22. PubMed ID: 11001763
[TBL] [Abstract][Full Text] [Related]
24. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
Tayarani-Binazir KA; Jackson MJ; Strang I; Jairaj M; Rose S; Jenner P
Behav Pharmacol; 2012 Apr; 23(2):126-33. PubMed ID: 22236652
[TBL] [Abstract][Full Text] [Related]
25. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
26. Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs.
Furuta Y; Hashimoto K; Iwatsuki K; Takeuchi O
Br J Pharmacol; 1973 Jan; 47(1):77-84. PubMed ID: 4717022
[TBL] [Abstract][Full Text] [Related]
27. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes.
Musso NR; Brenci S; Setti M; Indiveri F; Lotti G
J Clin Endocrinol Metab; 1996 Oct; 81(10):3553-7. PubMed ID: 8855800
[TBL] [Abstract][Full Text] [Related]
28. The pharmacology of Parkinson's disease: basic aspects and recent advances.
Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
[TBL] [Abstract][Full Text] [Related]
29. On the mechanism of L-dopa-induced postural hypotension in the cat.
Dhasmana KM; Spilker BA
Br J Pharmacol; 1973 Mar; 47(3):437-51. PubMed ID: 4147189
[TBL] [Abstract][Full Text] [Related]
30. Dopa in plasma increases during acute exercise and after exercise training.
Devalon ML; Miller TD; Squires RW; Rogers PJ; Bove AA; Tyce GM
J Lab Clin Med; 1989 Sep; 114(3):321-7. PubMed ID: 2504856
[TBL] [Abstract][Full Text] [Related]
31. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of tryptophan hydroxylase by benserazide and other catechols.
Johansen PA; Wolf WA; Kuhn DM
Biochem Pharmacol; 1991 Feb; 41(4):625-8. PubMed ID: 1997008
[TBL] [Abstract][Full Text] [Related]
33. Metabolism and blood-brain clearance of L-3,4-dihydroxy-[3H]phenylalanine ([3H]DOPA) and 6-[18F]fluoro-L-DOPA in the rat.
Cumming P; Ase A; Diksic M; Harrison J; Jolly D; Kuwabara H; Laliberté C; Gjedde A
Biochem Pharmacol; 1995 Sep; 50(7):943-6. PubMed ID: 7575677
[TBL] [Abstract][Full Text] [Related]
34. The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit.
Friedgen B; Halbrügge T; Graefe KH
Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb; 347(2):155-61. PubMed ID: 8474536
[TBL] [Abstract][Full Text] [Related]
35. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
Jonkers N; Sarre S; Ebinger G; Michotte Y
J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
[TBL] [Abstract][Full Text] [Related]
36. Increased spillover of dopa into arterial blood during dietary salt loading.
Grossman E; Hoffman A; Chang PC; Keiser HR; Goldstein DS
Clin Sci (Lond); 1990 Apr; 78(4):423-9. PubMed ID: 2160359
[TBL] [Abstract][Full Text] [Related]
37. Apical and basolateral uptake and intracellular fate of dopamine precursor L-dopa in LLC-PK1 cells.
Soares-Da-Silva P; Serrão MP; Vieira-Coelho MA
Am J Physiol; 1998 Feb; 274(2):F243-51. PubMed ID: 9486218
[TBL] [Abstract][Full Text] [Related]
38. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
39. Cerebral 6-[(18)F]fluoro-L-DOPA (FDOPA) metabolism in pig studied by positron emission tomography.
Danielsen EH; Smith DF; Gee AD; Venkatachalam TK; Hansen SB; Hermansen F; Gjedde A; Cumming P
Synapse; 1999 Sep; 33(4):247-58. PubMed ID: 10421705
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
Lieberman A; Estey E; Gopinathan G; Ohashi T; Sauter A; Goldstein M
Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
